Complex therapy of patients with chronic lower limb ischemia by angiogenesis gene inductors:immediate and long-term results

A V Gavrilenko,; D A Voronov,; N P Bochkov

doi:10.23868/gc121560

Genes & Cells ›› 2011, Vol. 6 ›› Issue (3) : 84 -88. DOI: 10.23868/gc121560

Articles

other

Complex therapy of patients with chronic lower limb ischemia by angiogenesis gene inductors:immediate and long-term results

Author information +

History +

PDF

Abstract

The controlled study results of using therapeuticangiogenesis in multimodality therapy of patients with chroniclower limb ischemia (CLLI) are presented. 134 patients (74ones comprised the target group and 60 patients were thecontrols) with CLLI IIb-III stages according to the Fontaine-Pokrovsky classification were included into the study.Angiogenesis stimulation was used both as a separatetreatment modality in combination with routine conservativetherapy and as an adjuvant to reconstructive vascularsurgery. It is proved that genetically engineered angiogenesisstimulators can be used in a multimodality therapy of patientswith CLLI, demonstrating satisfactory tolerance and safety.Therapeutic angiogenesis technologies have been shown tobe applied as an independent therapy and as in combinationwith reconstructive vascular surgery to improve a long-termoutcome of the latter.

Cite this article

Download citation ▾

A V Gavrilenko,, D A Voronov,, N P Bochkov. Complex therapy of patients with chronic lower limb ischemia by angiogenesis gene inductors:immediate and long-term results. Genes & Cells, 2011, 6(3): 84-88 DOI:10.23868/gc121560

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Бокерия Л.А., Демидова О.А., Аракелян В.С. и др. Опыт лечения хронической ишемии нижних конечностей с помощью генного препарата сосудисто-эндотелиального фактора роста VEGF165 - ангиостимулина. Бюллетень НЦССХ им. А.Н. Баку- лева РАМН «Сердечно-сосудистые заболевания» 2006; 7(1): 74-81.

[2]	Бочков Н.П., Константинов Б.А., Гавриленко А.В. и др. Генно- инженерные технологии в лечении хронической ишемии нижних конечностей. Вестник РАМН 2006; 9-10: 6-11.

[3]	Константинов Б.А., Бочков Н.П., Гавриленко А.В. и др. Экс- периментальные и клинические результаты использования генно- инженерных конструкций с геном ангиогенина в лечении хронической ишемии нижних конечностей. Медицинская генетика 2005;4(7): 327-31.

[4]	Lederman R.J., Mendelsohn F.O., Anderson R.D. et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC study). Lancet 2002; 359:2053-8.

[5]	Makinen K., Manninen H., Hedman M. et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol. Ther. 2002; 6: 127-33.

[6]	Rajagopalan S., Mohler E.R., Lederman R.J. et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease. Circulation 2003; 108: 1933-8.